World News
The FDA is requiring new safety warnings for popular GLP-1 weight-loss medications over a potential increased risk of a rare eye condition that can cause sudden vision loss.
The US Food and Drug Administration βon Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.
World News
The risk appears small and data is mixed, but FDA wants patients to be aware.
World News
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
Technology
The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
World News
Six unproven peptides popular with MAHA now under "enforcement discretion policy."
The US Food and Drug Administration is proposing changes to nutrient requirements for infant formula. The update marks the first nutrition review for formula in nearly 30 years, the agencyβs acting director, Kyle Diamantas, said Thursday.
A plan to give people in the United States easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with its development.